General Principles - The company establishes a management system for the deferral and exemption of information disclosure to regulate the behavior of the company and other information disclosure obligors, enhance information disclosure supervision, and protect investors' legitimate rights and interests [1][2] - The company and other information disclosure obligors must disclose information truthfully, accurately, completely, timely, and fairly, and must not abuse deferral or exemption to evade disclosure obligations or mislead investors [1][2] Scope and Management of Deferral and Exemption - The company can exempt disclosure if there is sufficient evidence that the information involves state secrets or other matters that may violate state confidentiality regulations [2][3] - The company has an obligation to protect state secrets and must not leak them through any form of information disclosure or interaction with investors [2][3] - Information involving commercial secrets can be deferred or exempted if it meets certain conditions, such as being core technology information that could lead to unfair competition if disclosed [2][3] Internal Review Procedures - The company’s board secretary is responsible for organizing and coordinating the deferral and exemption of information disclosure, with the board office handling daily operations [5] - If a deferral or exemption application is not approved by the board secretary or the chairman, the company must disclose the information in accordance with securities regulatory requirements [5] Reporting and Documentation - The company must register details of the deferral or exemption, including the type of documents involved and the internal review procedures [4][5] - After the annual, semi-annual, or quarterly reports are announced, the company must submit relevant registration materials regarding deferrals or exemptions to the local securities regulatory bureau and stock exchange within ten days [4][5]
盘龙药业: 信息披露暂缓、豁免管理制度